GRI Bio shares surge 20.66% after-hours on positive Phase 2a IPF data showing safety, biomarker improvements, and FVC gains.

GRI Bio surged 20.66% in after-hours trading following the release of positive Phase 2a trial data for GRI-0621 in idiopathic pulmonary fibrosis (IPF). The trial met primary safety endpoints, with no serious adverse events, and demonstrated favorable biomarker shifts indicating fibrosis resolution and alveolar basement membrane repair. Notably, 39% of treated subjects showed increased forced vital capacity (FVC) at 12 weeks compared to 80% of placebo subjects experiencing declines. These results highlight the drug’s potential as a disease-modifying therapy with a differentiated safety profile, addressing a significant unmet need in IPF treatment. The data reinforce GRI Bio’s pipeline strength and position the company for advanced clinical development, driving investor optimism.